The purpose of this program is to provide compassionate use of APT-1011 for adult and adolescent patients with eosinophilic esophagitis (EoE) who are unable or ineligible to enroll in an APT-1011 clinical study or have failed available treatment options

To learn if one kind of treatment approach, either (1) endoscopic surveillance or (2) endoscopic eradication therapy, is better, the same, or worse for treating patients with Barrett's esophagus and low-grade dysplasia.

we propose the creation of a prospective multi-center registry of patients with IBD and EIM, initially focusing on peripheral arthritis, the most common and understudied EIM, to better understand clinical course and management.

The Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) is doing this study because they want to learn more about eosinophilic gastrointestinal disorders (EGIDs).

This is an anonymous international research survey of primary care physicians (general practitioners), conducted to enhance understanding of diagnostic and treatment practices for irritable bowel syndrome (IBS) among such physicians in the U.S. and Europe, and to assess their knowledge and use of the Rome IV diagnostic criteria, which are the current recommended formal standard for diagnosis of the disorder.

Researchers are studying the long-term safety and tolerability of cendakimab for patients with eosinophilic esophagitis ("EoE"). The researchers hope to provide evidence to prove that cendakimab is a safe and effective medication for long-term EoE treatment.

The purpose of this study is to compare two different endoscopic techniques that are used to help patients feel better when they have a blockage from cancer in their stomach or first part of the small intestines.

To create a multi-centered prospective registry of individuals ≥60 years ("older adults") with IBD to quantify prevalence, incidence and progression of frailty, multi-morbidity, physical and cognitive impairment

To generate real world evidence on SOC (surgical interventions) for treating complex fistulizing conditions and related outcomes (clinical and patient reported) among patients with the following conditions: CPF-CD, CD- RVF, and CCF.

To assess hepatitis C virus treatment and hepatocellular carcinoma surveillance within practices and gauge the feasibility of a program to implement point-of-care risk stratification tools and screening referral systems.